Tailoring chemo for nasopharyngeal cancer using EBV-DNA and MRI
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have nasopharyngeal carcinoma (a type of throat cancer) that is stage II or III, with certain subtypes as confirmed by biopsy.
- Your blood must have measurable levels of EBV-DNA (a virus marker related to your cancer).
- You need to be in generally good health, able to perform daily activities, and have adequate organ function (like kidney, liver, and blood counts).
- You cannot have cancer that has spread to other parts of the body, and you must not have had prior chemotherapy, targeted therapy, immunotherapy, or radiation for this cancer.
- You cannot have certain active infections (like hepatitis B, hepatitis C, HIV), autoimmune diseases, or other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of radiation is just as effective as the standard dose for people with early-stage nasopharyngeal cancer, and aims to reduce side effects while keeping the cancer under control.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.